Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | APP | P05067 | 2/20 | 0.35 |
| ▸ | SNCA | P37840 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2644689 | 0.88 | MAPT (0.43) | KDM4EALDH1A1MAPTATM | |
| SCHEMBL2644737 | 0.83 | POLB (0.40) | ALDH1A1MAPTTDP1MAPK1 | |
| SCHEMBL2644120 | 0.83 | RORC (0.36) | PARP1KDM4EALDH1A1GAAMAPT | |
| SCHEMBL2644018 | 0.81 | CACNA1H (0.36) | KDM4EALDH1A1GAAMAPTHTT | |
| SCHEMBL2645436 | 0.78 | KDM4E (0.45) | KDM4EALDH1A1MAPTHTTATM | |
| SCHEMBL2644090 | 0.77 | ALDH1A1 (0.41) | KDM4EALDH1A1GAATSHRMAPT | |
| SCHEMBL2643582 | 0.75 | MAPT (0.40) | KDM4EALDH1A1MAPTHTTATM | |
| SCHEMBL2644694 | 0.73 | MAPT (0.39) | KDM4EALDH1A1MAPTATM | |
| SCHEMBL2643817 | 0.73 | HTT (0.37) | MAPTHTT | |
| SCHEMBL2645157 | 0.73 | MAPT (0.41) | KDM4EALDH1A1MAPTHTTRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796313-B2 | Substituted dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-08-05 | — | — | US | disclosed |
| CN-101316836-A | Substituted dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA NV (BE) | 2008-12-03 | — | — | CN | disclosed |
| US-20070099930-A1 | Substituted Dihydroisoindolones As Allosteric Modulators of Glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099930-A1 | Substituted Dihydroisoindolones As Allosteric Modulators of Glucokinase | GCK, GCKR, GPR119 | PARP1 3545/4885KDM4E 1206/4885ALDH1A1 1552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.